Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS) (RETIMUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04289909
Recruitment Status : Not yet recruiting
First Posted : February 28, 2020
Last Update Posted : February 28, 2020
Sponsor:
Collaborator:
Biogen
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France

Tracking Information
First Submitted Date  ICMJE February 25, 2020
First Posted Date  ICMJE February 28, 2020
Last Update Posted Date February 28, 2020
Estimated Study Start Date  ICMJE March 2020
Estimated Primary Completion Date October 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 26, 2020)
Quantification of retinal perivascular cuff width across MS phenotypes [ Time Frame: Baseline ]
The primary endpoint is to quantify retinal perivascular cuff width across MS phenotypes, compared among a group of control at baseline.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: February 26, 2020)
  • Variation of size of perivascular sheathing [ Time Frame: month 3 and month 6 ]
    Variation of size of perivascular sheathing along retinal vessels in the posterior pole during follow up (at month 3 and month 6) in patients with MS and a group of control
  • Clinical disability measure with EDSS [ Time Frame: month 3 and month 6 ]
    Evolution of Clinical disability: Expanded Disability Status Scale (EDSS: 0: normal neurological exam; 10 : death of the patient) at month 3 for MS patients with optic neuritis and at month 6 for all MS patients
  • Clinical disability measured with MSFC [ Time Frame: month 3 and month 6 ]
    Evolution of Clinical disability: Multiple Sclerosis Functional Composite (MSFC) at month 3 for MS patients with optic neuritis and at month 6 for all MS patients
  • Number of relapses [ Time Frame: month 3 and month 6 ]
    Evolution of Clinical disability: number of relapses at month 3 for MS patients with optic neuritis and at month 6 for all MS patients
  • Presence of disc oedema measured at Optical Coherence Tomography (OCT) measurements [ Time Frame: month 3 and month 6 ]
    Evolution of OCT measurements (presence of disc oedema) at month 3 for MS patients with optic neuritis and at month 6 for all MS patients
  • RNLF thickness measured at Optical Coherence Tomography (OCT) measurements [ Time Frame: month 3 and month 6 ]
    Evolution of OCT measurements : retinal nerve fiber layer thickness (RNFL, µm) at month 3 for MS patients with optic neuritis and at month 6 for all MS patients
  • parenchymal T2 lesion volume at MRI [ Time Frame: Baseline ]
    Evolution of MRI metrics: parenchymal T2 lesion volume
  • gadolinium enhanced T1 lesion at MRI [ Time Frame: Baseline ]
    Evolution of MRI metrics: gadolinium enhanced T1 lesion
  • optic nerve cross-sectional area at MRI [ Time Frame: Baseline ]
    Evolution of MRI metrics: optic nerve cross-sectional area
  • Hyperintensity on the optic nerve at MRI [ Time Frame: Baseline ]
    Evolution of MRI metrics: Hyperintensity on the optic nerve
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Official Title  ICMJE Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics
Brief Summary Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes occurring along the optic nerve of the brain parenchyma. Indeed, our team has been able to develop a quantitative method to measure the perivascular infiltrate in the retina of patients with various inflammatory retinal disease. It has been observed in MS patients that this perivascular infiltrate can also be detected in the retina. However, its distribution across MS phenotypes (relapsing or progressive MS, with and without optic neuritis) is still unknown.
Detailed Description

This is a monocentric pathophysiological, interventional, prospective, open label, non-randomized pilot study which aims to identify in patients with MS at different stages if the presence of retinal perivascular inflammation can be detected and quantified using adaptive optics, which is a non-invasive examination.

Investigators will recruit MS patients in 3 subgroups, depending on their phenotype (Relapsing Remitting Multiple Sclerosis (RRMS) without optic neuritis, RRMS with optic neuritis, progressive MS), with 15 patients in each group.

15 healthy volunteers (HV) will also be enrolled.

The comparison of these groups is necessary to determine if there are significant differences, allowing us to highlight biomarkers in MS patients in order to enable highly efficient and robust trials designs in the future.

To test the hypothesis, the study has 3 visits over 6 months (M0, M3 and M6). Neurological evaluation, blood sample, imaging, ophthalmologic evaluation and Adaptive optics ophthalmoscopy assessments will be performed.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE
  • Relapsing Remitting Multiple Sclerosis
  • Progressive Multiple Sclerosis
  • Optic Neuritis
  • Eye Diseases
  • Optic Nerve Diseases
  • Nervous System Diseases
  • Multiple Sclerosis
Intervention  ICMJE Other: Adaptive Optics Ophthalmoscopy (AOO)
AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
Study Arms  ICMJE
  • MS patients
    RRMS Patients with optic neuritis, RRMS patients without optic neuritis or Progressive MS patients
    Intervention: Other: Adaptive Optics Ophthalmoscopy (AOO)
  • Control group
    Healthy volunteers
    Intervention: Other: Adaptive Optics Ophthalmoscopy (AOO)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: February 26, 2020)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 2022
Estimated Primary Completion Date October 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Group 1:

  • Age between 18 and 60 years old.
  • Relapsing remitting MS (criteria of McDonald 2017)
  • Less than 10 years of disease duration
  • Subject who has never presented a clinical episode of optic neuritis
  • Affiliation to a social security scheme or beneficiary of such a scheme

Group 2:

  • Age between 18 and 60 years old
  • Relapsing remitting MS (criteria of McDonald 2017)
  • Less than 10 years of disease duration
  • Subject presenting an acute episode of retrobulbar optic neuritis within 3 months from onset
  • After optimal treatment for the retrobulbar optic neuritis
  • Affiliation to a social security scheme or beneficiary of such a scheme

Group 3:

  • Age between 18 and 60 years old
  • Primary or Secondary progressive multiple sclerosis within 10 years of progressive phase;
  • Affiliation to a social security scheme or beneficiary of such a scheme

Group 4 (Healthy Subjects):

  • Age between 18 and 60 years old
  • Affiliation to a social security scheme or beneficiary of such a scheme

Exclusion Criteria:

For all patients (Group 1; 2; 3):

  • Corticosteroid treatment within one month from inclusion
  • Other neurological, ophthalmologic or systemic disease;
  • Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion)
  • Severe renal dysfunction (glomerular filtration rate < 30mL/min). This non-inclusion criteria will be verified by serum creatinine test within six months from inclusion;
  • Contraindication for MRI;
  • Pregnancy or breast-feeding;
  • Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly)
  • Incapacity to understand or sign the consent form;
  • Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.

For healthy subjects (Group 4):

  • Neurological, ophthalmologic or systemic disease;
  • Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion);
  • Contraindication for MRI;
  • Pregnancy or breast-feeding;
  • Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly)
  • Incapacity to understand or sign the consent form;
  • Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Céline Louapre + 33 1 42 16 57 66 celine.louapre@aphp.fr
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04289909
Other Study ID Numbers  ICMJE 19-25
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Institut National de la Santé Et de la Recherche Médicale, France
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Institut National de la Santé Et de la Recherche Médicale, France
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Biogen
Investigators  ICMJE
Principal Investigator: Celine Louapre, MD, PHD Institut du Cerveau et de la Moelle Epinière
PRS Account Institut National de la Santé Et de la Recherche Médicale, France
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP